Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases
Idiopathic Pulmonary Fibrosis Clinical Trials
A listing of Idiopathic Pulmonary Fibrosis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Jasper : 1199.33.01012 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Arizona
Phoenix : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Phoenix : 1199.33.01003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Phoenix : Arizona Pulmonary Specialists
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Scottsdale : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Tucson : University of Arizona
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
California
San Francisco : University California-San Francisco
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Stanford : Stanford University Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Los Angeles : VA Greater LA Health Care System-UCLA
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Los Angeles : David Geffen School of Medicine, UCLA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Sacramento : University of California- Davis Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
San Francisco : Investigational Site Number 840008
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Santa Barbara : 1199.33.01026 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Torrance : 1199.33.01007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Connecticut
Danbury : 1199.33.01006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Stamford : 1199.33.01017 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Florida
Gainesville : University of Florida/Pulmonary, Critical Care & Sleep Medicine
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Miami : University of Miami
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Clearwater : Bay Area Chest Physicians
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville : Investigational Site Number 840009
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville : Investigational Site Number 840011
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Tampa : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Illinois
Chicago : University of Chicago
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Chicago : Investigational Site Number 840006
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Joliet : Investigational Site Number 840004
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Maywood : Investigational Site Number 840005
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Kansas
Wichita : Wichita Clinic, PA
A Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)
Wichita : Via Christi Research
Evaluate the Effect of Different Doses of SAR156597 in Idiopathic Pulmonary Fibrosis
View More »
Wichita : 1199.33.01023 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Wichita : Investigational Site Number 840002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Kentucky
Louisville : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Louisville : Kentuckiana Pulmonary Associates
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Massachusetts
Boston : Beth Israel Deaconess Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Boston : Brigham and Women's Hospital
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Boston : Massachusetts General Hospital
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Boston : Brigham & Women's Hospital -Pulmonary and Critical Care Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Minnesota
Minneapolis : 1199.33.01005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Minneapolis : Investigational Site Number 840003
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Missouri
St. Louis : Washington University School of Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center Pulmonary Dept.
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Lebanon : 1199.33.01027 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
New Jersey
Newark : University of Medicine and Dentistry of New Jersey
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Summit : Pulmonary & Allergy Associates, P.A.
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)
Summit : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
New York
Mineola : Winthrop University Hospital Clinical Trials Center
Idiopathic Pulmonary Fibrosis
View More »
Albany : 1199.33.01041 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Jamaica : 1199.33.01010 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
New York : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
New York : Investigational Site Number 840013
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
North Carolina
Durham : Duke University Medical Center
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Durham : Novartis Investigative Site
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ohio
Cleveland : Cleveland Clinic
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Cincinnati : The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Cincinnati : Investigational Site Number 840014
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Cleveland : Cleveland Clinic
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Columbus : Ohio State University, Martha Morehouse Medical Plaza
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Oregon
Portland : 1199.33.01004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Pennsylvania
Pittsburgh : University of Pittsburgh Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Pittsburgh : 1199.33.01032 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Pittsburgh : Allegheny General Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
South Carolina
Charleston : 1199.33.01024 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Charleston : Investigational Site Number 840010
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Tennessee
Nashville : Vanderbilt University Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Shelbyville : 1199.33.01016 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Texas
Houston : Baylor College of Medicine and The Methodist Hospital
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Houston : Investigational Site Number 840012
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Longview : 1199.33.01019 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
McKinney : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
McKinney : 1199.33.01021 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
San Antonio : 1199.33.01001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Utah
Salt Lake City : University of Utah
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Virginia
Lynchburg : 1199.33.01002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Wisconsin
Milwaukee : Aurora St. Luke's Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Australia
Camperdown : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Camperdown : 1199.33.61001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Chermside : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Concord : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Concord : 1199.33.61002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Darlinghurst : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Frankston : 1199.33.61005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Melbourne : 1199.33.61004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
New Lambton : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Prahran : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Toorak Gardens : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Woodville South : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Belgium
Bruxelles : 1199.33.32004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Leuven : 1199.33.32001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Leuven : Investigational Site Number 056001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Yvoir : 1199.33.32002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Canada
Edmonton : Investigational Site Number 124003
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Hamilton : Investigational Site Number 124001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Vancouver : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Vancouver : Investigational Site Number 124002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Windsor : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Chile
Concepción : Investigational Site Number 152004
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Santiago : Investigational Site Number 152001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Santiago : Investigational Site Number 152002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Santiago : Investigational Site Number 152003
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
China
Beijing : Peking Union Medical College Hospital
Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
Finland
Vantaa : 1199.33.35802 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
France
BOBIGNY Cedex : 1199.33.33002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Lille Cedex : 1199.33.33009 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Lyon cedex : 1199.33.33011 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Marseille : 1199.33.33013 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Montpellier Cedex 5 : 1199.33.33008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Nice Cedex 1 : 1199.33.33003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Paris : 1199.33.33006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Paris Cedex 18 : 1199.33.33001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Reims Cedex : 1199.33.33007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Rennes Cedex 9 : 1199.33.33004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Toulouse Cedex 9 : 1199.33.33012 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Germany
Bamberg : 1199.33.49008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Berlin : 1199.33.49009 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Bochum : Klinik III für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufs¬genossen-schaftliches Universitätsklinikum Bergmannsheil GmbH
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Coswig : 1199.33.49010 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Donaustauf : 1199.33.49005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Essen : 1199.33.49001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Freiburg/Breisgau : 1199.33.49002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Hannover : Klinik für Pneumologie, Medizinische Hochschule Hannover
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Heidelberg : 1199.33.49007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Heidelberg : Pneumologie und Beatmungsmedizin, Thoraxklinik,Universitätsklinikum
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Immenhausen : 1199.33.49013 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Leipzig : Abteilung für Pneumologie Department Innere Medizin, Neurologie und Dermatologie Universitätsklinikum Leipzig AöR
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Mainz : 1199.33.49004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
München : 1199.33.49011 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Greece
Athens : 1199.33.30005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Heraklion : 1199.33.30001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Italy
Forli' : 1199.33.39008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Modena : 1199.33.39001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Monza : 1199.33.39007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Napoli : 1199.33.39011 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Pisa : 1199.33.39006A Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Pisa : 1199.33.39006B Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Roma : 1199.33.39010 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Korea, Republic of
Bucheon : 1199.33.82002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Incheon : 1199.33.82004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Seoul : 1199.33.82006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Seoul : 1199.33.82007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Seoul : 1199.33.82001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Seoul : 1199.33.82003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Mexico
Mexico City : Investigational Site Number 484003
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Monterrey : Investigational Site Number 484002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Netherlands
Amsterdam : 1199.33.31002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Nieuwegein : 1199.33.31001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Rotterdam : 1199.33.31003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Portugal
Coimbra : 1199.33.35105 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Lisboa : 1199.33.35102 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Lisboa : 1199.33.35103 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Porto : 1199.33.35101 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Spain
Barcelona : 1199.33.34004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Barcelona : 1199.33.34003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Barcelona : Investigational Site Number 724002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Barcelona : Investigational Site Number 724001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
L´Hospitalet de Llobregat : 1199.33.34005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Sevilla : 1199.33.34008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
United Kingdom
Aberdeen : 1199.33.44006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Birmingham : 1199.33.44003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Birmingham : 1199.33.44005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Liverpool : 1199.33.44004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
London : 1199.33.44002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
London : Royal Brompton Hospital
IPF Drug Deposition Study
London : Royal Brompton Hospital
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Nottingham : Nottingham University Hospitals NHS Trust
Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
Oxford : 1199.33.44008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Westbury on Trym : 1199.33.44001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
